Trends in anti‐D immune globulin for childhood immune thrombocytopenia: Usage, response rates, and adverse effects

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American journal of hematology/oncology

• Publication date

  2012-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ajh.22261PMID 22190130PMCID PMC3767405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population

  2012cited by this paper
• Acquired factor V inhibitor complicating warfarin therapy

  2011cited by this paper
• The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

  2011cited by this paper
• Management of intentional superwarfarin poisoning with long-term vitamin K and brodifacoum levels

  2011cited by this paper
• Acquired factor V inhibitors: a systematic review

  2011cited by this paper
• Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.

  2010cited by this paper
• Manifestations of superwarfarin ingestion: A plea to increase awareness

  2010cited by this paper
• Advances in understanding the bleeding diathesis in factor V deficiency

  2009cited by this paper
• Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

  2009cited by this paper
• Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support

  2009cited by this paper
• Superwarfarin poisoning: A report of two cases and review of the literature

  2007cited by this paper
• Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation

  2004cited by this paper
• Grading of hemorrhage in children with idiopathic thrombocytopenic purpura.

  2002influential reference
• Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG.

  2002cited by this paper
• Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura

  2002cited by this paper
• Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients.

  2000cited by this paper
• Clinical and laboratory manifestations of anti-factor V antibodies.

  1999cited by this paper
• Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin.

  1999cited by this paper
• Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations.

  1998cited by this paper
• Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children.

  1998cited by this paper
• Anti-D: mechanisms of action.

  1998cited by this paper
• Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras.

  1994cited by this paper
• Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity.

  1992cited by this paper
• Epitope mapping of functional domains of human factor Va with human and murine monoclonal antibodies. Evidence for the interaction of heavy chain with factor Xa and calcium.

  1987cited by this paper
• Factor V inhibitor associated with immune complex formation.

  1986cited by this paper
• A spontaneous factor V inhibitor with unexpected laboratory features.

  1986cited by this paper
• Isolation and study of an acquired inhibitor of human coagulation factor V.

  1986cited by this paper
• Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D))

  1984cited by this paper
• Hemorrhagic death associated with a high titer factor V inhibitor

  1978cited by this paper
• Detection of factor VIII inhibitors with the partial thromboplastin time.

  1977cited by this paper
• Factor V inhibitor and bullous pemphigoid.

  1977cited by this paper
• Observations on a Factor‐V Inhibitor

  1975cited by this paper
• Factor V anticoagulants: clinical, biochemical, and immunological observations.

  1970cited by this paper

• Treatment Landscape in Pediatric Immune Thrombocytopenia: Addressing Unmet Needs

  2025cites this paper
• Small Molecule Drugs That Inhibit Phagocytosis

  2023cites this paper
• Mechanism of Small Molecule Inhibitors of Phagocytosis

  2023cites this paper
• UDC: 616

  2023cites this paper
• Pediatric immune thrombocytopenia (ITP) treatment

  2021cites this paper
• Efficacy and Safety of Anti‐D Immunoglobulins versus Intravenous Immunoglobulins for Immune Thrombocytopenia in Children: Systematic Review and Meta‐analysis of Randomized Controlled Trials

  2019cites this paper
• The Treatment of Immune Thrombocytopenia

  2018cites this paper
• When and how to treat childhood immune thrombocytopenia.

  2016cites this paper
• High dose Intravenous Anti-D Immune Globulin is More Effective and Safe in Indian Paediatric Patients of Immune Thrombocytopenic Purpura.

  2016cites this paper
• Influence of the American Society of Hematology guidelines on the management of newly diagnosed childhood immune thrombocytopenia.

  2014cites this paper
• Acute hemolysis after intravenous immunoglobulin amid host factors of ABO‐mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes

  2014cites this paper
• Acute renal failure in a child with thrombocytopenic purpura caused by acute Epstein-Barr virus infection after treatment with anti-D immunoglobulin.

  2013cites this paper
• Anti‐D immunoglobulin therapy for pediatric ITP: Before and after the FDA's black box warning

  2013cites this paper
• Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia?

  2013cites this paper
• Intramuscular anti‐D in chronic immune thrombocytopenia children with severe thrombocytopenia

  2013cites this paper
• Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.

  2012cites this paper
• A case of factor V inhibitor with complete correction of the PT and aPTT upon mixing

  2012cites this paper